Evidence map›Paper›PMID 40186034›Full record

ArticleDermatology and therapy2025

Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions.

Kenneth B Gordon, Yayoi Tada, Milan J Anadkat, Siew Eng Choon, Boni Elewski, Jonathan N Barker, Arash Mostaghimi, Kilian Eyerich, Ming Tang, Thomas Haeufel and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Kenneth B GordonDepartment of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA. kegordon@mcw.edu.ORCID http://orcid.org/0000-0002-9347-0292
Yayoi TadaDepartment of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0003-3743-135X
Milan J AnadkatDivision of Dermatology, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-0723-3953
Siew Eng ChoonDepartment of Dermatology, Clinical School Johor Bahru, Hospital Sultanah Aminah Johor Bahru, Monash University, Subang Jaya, Malaysia.ORCID http://orcid.org/0000-0002-7796-5746
Boni ElewskiUniversity of Alabama, Birmingham, AL, USA.ORCID http://orcid.org/0000-0002-1475-2874
Jonathan N BarkerFaculty of Life Sciences and Medicine, St. John's Institute of Dermatology, King's College London, London, UK.ORCID http://orcid.org/0000-0002-9030-183X
Arash MostaghimiDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6084-5617
Kilian EyerichDepartment of Dermatology and Venerology, Medical Centre, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0003-0094-2674
Ming TangBoehringer Ingelheim (China) Investment Co. Ltd, Shanghai, China.ORCID http://orcid.org/0000-0002-6451-8648
Thomas HaeufelBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Christian ThomaBoehringer Ingelheim International GmbH, Biberach, Germany.ORCID http://orcid.org/0000-0002-0967-2028
Diamant ThaçiInstitute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Lübeck, Germany.ORCID http://orcid.org/0000-0001-8513-550X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40186034
PMCPMC12092308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.